Pfizer Eyes Massive New Market as U.S. Poised to See "Staggering Number” of Cardiomyopathy Cases

There’s a new blockbuster heart disease market in town—and it's set to explode in size. As Pfizer, Bristol Myers Squibb and Alnylam are already fighting for their share of prescriptions, a new report finds they'll have millions more patients to treat in the coming years.

That disease is cardiomyopathy, an umbrella term covering a series of problems with the heart muscle, where the walls of the heart chambers have become stretched, thickened or stiff.

Analysts at GlobalData crunched the numbers and found that by 2031, cases of cardiomyopathy will balloon to 7 million around the world, but most of the growth will come from the U.S. Some 2.3 million cases are expected in the States by that date.

Though bad news for the health of the nation, that growth in cardiomyopathy is a bullish report for three pharmas: Pfizer, BMS and Alnylam, which have scored fresh FDA approvals and trial wins that are tackling some of these forms of cardiomyopathy.

Source: Fierce Pharma

Follow:?
@G3News